# A Three-part First-in-human Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB-UCN2 in Healthy Lean and Obese Participants and Participants With T2D

Study · id `cardio:ct-nct07702890` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07702890](<https://clinicaltrials.gov/study/NCT07702890>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07702890

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 188 participants.

## Technical summary

Registry record NCT07702890. Randomized; double masking; primary purpose treatment. Start 2026-07-27 (actual); primary completion 2028-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 1/2
- Enrolled: 188 participants (planned count; ClinicalTrials.gov record NCT07702890, source copy `cardio:ctgov-nct07702890-2026-09-10`, retrieved 2026-10-26)
- Started: 2026-07-27 (actual) (ClinicalTrials.gov record NCT07702890, source copy `cardio:ctgov-nct07702890-2026-09-10`, retrieved 2026-10-26)
- Primary completion: 2028-12 (anticipated) (ClinicalTrials.gov record NCT07702890, source copy `cardio:ctgov-nct07702890-2026-09-10`, retrieved 2026-10-26)
- Completion: 2028-12 (anticipated) (ClinicalTrials.gov record NCT07702890, source copy `cardio:ctgov-nct07702890-2026-09-10`, retrieved 2026-10-26)
- Countries: Germany (ClinicalTrials.gov record NCT07702890, source copy `cardio:ctgov-nct07702890-2026-09-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07702890-2026-09-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Three-part First-in-human Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB-UCN2 in Healthy Lean and Obese Participants and Participants With T2D
- Condition: Obesity
- Condition: Type 2 Diabetes
- Intervention (Drug): GUB-UCN2
- Intervention (Drug): Placebo
- Lead sponsor: Gubra A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 283721dde31acb7545451d6fa18729b90bd4b460ab61e98d31b1c1f5dd0e4cb3
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
